Solvonis Therapeutics plc

Here is the public summary page for Solvonis Therapeutics plc. Please login to see the complete information for Solvonis Therapeutics plc including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Solvonis Therapeutics plc stacks up relative to its peers.

Darwin Score+8
TickerSVNS
Latest Price0.00 GBP as of close on 15-Aug-2025
3 Month price range0.00 to 0.00 GBP
CountryUK
RegionEurope
Description
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
See More ...
Company URLhttps://solvonis.com
See Darwins Full Analysis for Solvonis Therapeutics plc

Tell Me About

Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Solvonis Therapeutics plc. Further information and full detail is available when you login.

TMA PartFocus of AnalysisTMA Score
PriceAnalysis of performance, trend, RSI, OBV and moving averages+15
SentimentNews and Candle Patterns. +1
FundamentalsAnalyst Ratings, Valuation and Dividend analysis.0
FlowInstitutional, Fund and Insider buying and selling.0
ModelsForecast models.-8

Alerts

There are 4 live alerts for Solvonis Therapeutics plc.

Share Share on Facebook Share on Twitter Share on Threads Share on LinkedIn